Achondrogenesis Market research report- Forecast till 2030

Achondrogenesis Market Information: by type (type IA (Houston-Harris type), type IB (Fraccaro type), type II (Langer-Saldino type)), Diagnosis (Molecular Genetic Testing, Biochemical Testing), End User (Hospitals & Clinics) - Forecast till 2030

ID: MRFR/MED/3247-HCR | 85 Pages | Published By Rahul Gotadki on April 2023         

Achondrogenesis Market Speak to Analyst Request a Free Sample

Achondrogenesis Market Overview :

Achondrogenesis is a severe congential growth hormone deficiency that affects cartilage and bone development. This rare genetic disease is characterized by narrow chest, rounded abdomen, and extremely short limbs. There are majorly three types of achondrogenesis, type 1A, type 1B and type 2. Out of these three, type 1B is most severe and caused by mutations in the SLC26A2 gene. Achondrogenesis type 1B (ACG1B) is also known as Parenti-Fraccaro type. Achondrogenesis exhibits various symptoms such as, abdominal distention, flat face, anteverted nares, frontal bossing, lethal skeletal dysplasia, hydropsfetalis, abnormal enchondral ossification, and many others. According to the U.S National Library of Medicine, the incidence of 1A and 1B, whereas achondrogenesis type 2 occur in 1 in 40,000 to 60,000 newborns. The condition of achondrogenesis type 2 is mostly found in combination with hypochondrogenesis.

Appropriate treatment for the condition is unknown but to deal with the symptoms associated with achondrogenesis, palliative care is suggested by physicians. Genetic Counseling is also recommended to the people who have genetic disorders in their family history. Diagnosis or testing of achondrogenesis is based on histopathologic, clinical, and radiologic features. As per an article published in GeneReviews book, it is found that SLC26A2 is the only mutated gene known to cause ACG1B. Out of all the testing methods, molecular genetic testing is the most commonly used diagnosis for Achondrogenesis Type 1B. Molecular genetic testing method includes targeted mutation analysis, sequence analysis, and deletion/duplication analysis.

Notably, presence of mutated gene in the family history is the key factor driving the achondrogenesis market. As per the information suggested by National Center for Advancing Translational Sciences (NCATS), achondrogenesis type 1A and type 1B occur due to autosomal recessive inheritance which means each parent carry one copy of the mutated gene. However, it is also reported that achondrogenesis type 2 is an autosomal dominant disorder and typically found in people with no history of gene mutation in their family. Various other push factors such as, rise in facilities for patients affected by rare diseases, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the  achondrogenesis market.

Despite these drivers, there are some issues associated with achondrogenesis market. Challenges in research and development, and lack of skilled healthcare professionals in developing countries hinder the growth of achondrogenesis market to an extent.

It is estimated that achondrogenesis market is expected to grow USD 1.83 Billion at a CAGR 4.10% during the forecast period of 2023-2030.

Intended Audience

  • Pharmaceutical Companies

  • Surgical equipment Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


The achondrogenesis market is segmented on the basis of type, diagnosis, and end-users.

On the basis of type, achondrogenesis market is segmented into achondrogenesis type IA (Houston-Harris type), achondrogenesis type IB (Parenti-Fraccaro type), and achondrogenesis type II (Langer-Saldino type).

On the basis of diagnosis, achondrogenesis market is classified into physical examination, molecular genetic testing, and biochemical testing. Physical examination is further classified into X-ray, ultrasound, and others. Molecular genetic testing is also further segmented into Chorionic villus sampling (CVS), aminocentesis, and others.

On the basis of end-users, achondrogenesis market is segmented into hospital & clinics, diagnostic centers, research & academic institutes, and others.

Regional Analysis

The Americas dominate the achondrogenesis market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in achondrogenesis market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the achondrogenesis market in Europe region.

Asia Pacific is the fastest growing achondrogenesis market owing to the huge patient pool and developing healthcare technology.

Key Players

Some of key the players in the achondrogenesis market are Cook, Thermo Fisher Scientific, CooperSurgical Inc., Illumina, Inc., Siemens AG, FUJIFILM Holdings Corporation, Koninklijke, Philips N.V., Stryker, Toshiba Corporation, Invivoscribe, Abbott Molecular Inc., INVITROGEN CORPORATION, Roche Molecular Systems, Inc., and others.

Research MethodologyAchondrogenesis Market

Sources: Annual reports, Press release, White paper, and Company presentation


Report Scope:

Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   3.9% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cook, Thermo Fisher Scientific, CooperSurgical Inc., Illumina, Inc., Siemens AG, FUJIFILM Holdings Corporation, Koninklijke, Philips N.V., Stryker, Toshiba Corporation, Invivoscribe, Abbott Molecular Inc., INVITROGEN CORPORATION, Roche Molecular Systems, Inc., and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Presence of mutated gene in the family history
  • Increasing government assistance
  • Improvement in regulatory framework

  • Speak to Analyst Ask for Customization